Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JPA Express Deep Regrets over Decision on Lifting Online Sales Ban of OTC Drugs
The Japan Pharmaceutical Association (JPA) expressed its deep regrets on November 7 over the government’s decision the previous day to lift a ban on online sales of 99.8% of OTC drugs, along with new rules, and submit a bill to…
To read the full story
Related Article
- Online Sales Banned for Three Years after Rx-to-OTC Switch
November 7, 2013
ORGANIZATION
- EFPIA Urges Global-Level Launch Prices, Patent-Term Price Protection
June 26, 2026
- Industry Hails Japan Growth Roadmap, PhRMA Urges Follow-Through
June 25, 2026
- Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
June 22, 2026
- Think Tank Opposes Cap on Social Security Burden Ratio, Urges Pause in Off-Year Price Cuts
June 22, 2026
- Japanese Drug Makers Step Up Use of ASEAN Reliance Reviews
June 18, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…